Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Because there is limited data about long-term efficacy and safety about short-term use of
cilostazol adding to dual antiplatelet therapy in patients with long or multivessel coronary
artery disease after 2nd generation DES implantation, especially in biodegradable polymer
stent, the investigators will evaluate whether a 3-month use of cilostazol in addition to
dual antiplatelet therapy effectively reduces clinical adverse outcome at 1 year in subject
with long or multivessel coronary artery disease after biolimus-eluting stent implantation.